Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
41 pending office actions • 23 art units • 38 examiners • 0 of 41 (0%) have an AI response strategy ready • 35 patents granted in the last 365 days
Astrazeneca AB maintains a substantial patent portfolio within the Biotechnology & Pharmaceuticals technology area. The company currently faces 41 pending office actions, reflecting a high volume of active prosecution. These actions are distributed among 38 distinct examiners, suggesting that while the workload is large, it is spread across a wide array of individual reviewers.
The portfolio's reach extends across 23 distinct art units. This diversity indicates that the company's research and development efforts are broad, touching many different specialized sectors within the biotechnology and pharmaceutical fields. FETTEROLF, BRANDON J is identified as the busiest examiner for the portfolio.
FETTEROLF, BRANDON J is currently handling 2 busiest examiner pending actions. While this examiner has the highest individual workload for the company, these 2 actions represent a small fraction of the 41 pending office actions total. The fact that 38 distinct examiners are involved in 41 actions shows that most examiners are only handling a single case for the company. This decentralized prosecution environment requires the company to manage a large number of simultaneous administrative relationships across 23 distinct art units.
Based on the USPTO statutory response window for each pending office action. 13 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 13 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (2%) |
| §101 + other | 3 (7%) |
| §103 only | 8 (20%) |
| §102 only | 3 (7%) |
| §112 only | 6 (15%) |
| Double-patenting only | 2 (5%) |
| Double-patenting + other | 8 (20%) |
| Multi-statute (no §101) | 10 (24%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FETTEROLF, BRANDON J | 2 | 52.0% | +17.4% |
| GRIZER, CASSANDRA SENN | 2 | 75.0% | +18.8% |
| HAGHIGHATIAN, MINA | 2 | 46.1% | +39.3% |
| GAMBLE JR, RANDALL LEE | 1 | 51.4% | +27.6% |
| KRUSE, DAVID H | 1 | 81.3% | +9.6% |
| KOSAR, ANDREW D | 1 | 42.0% | +31.8% |
| CHICKS, ASHLI ARIANA | 1 | 60.6% | +50.3% |
| REICHERT, RACHELLE LEIGH | 1 | 30.2% | +33.2% |
| HEIN, DEVIN C | 1 | 46.1% | +29.5% |
| ROZOF, TIMOTHY R | 1 | 72.7% | +23.6% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18872994 | METHODS FOR UNIFIED CONCENTRATION AND BUFFER EXCHANGE | KRUSE, DAVID H | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17917333 | COMPOSITIONS AND METHODS FOR IMPROVED SITE-SPECIFIC MODIFICATION | ALLEN, SARAH ELIZABETH | 22d overdue |
| 18262934 | CLINICAL ENDPOINT ADJUDICATION SYSTEM AND METHOD | PATEL, SHERYL GOPAL | 17d overdue |
| 18590826 | COMPOSITIONS, METHODS AND SYSTEMS FOR AEROSOL DRUG DELIVERY | HAGHIGHATIAN, MINA | 17d overdue |
| 18252818 | PHARMACEUTICAL FORMULATION | PUTTLITZ, KARL J | 8d overdue |
| 18256484 | METHODS OF PRODUCING ADENOVIRUS | GRIZER, CASSANDRA SENN | 9d |
| 18855182 | PREDICTING ALBUMINURIA USING MACHINE LEARNING | HEIN, DEVIN C | 12d |
| 18564778 | METHODS OF TREATING BREAST CANCER | FETTEROLF, BRANDON J | 16d |
| 17754844 | MODULATORS OF PNPLA3 EXPRESSION | CHONG, KIMBERLY | 69d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17772187 | DRY POWDER FORMULATIONS CONTAINING LEUCINE AND TRILEUCINE | HAGHIGHATIAN, MINA | 19d overdue |
| 18590826 | COMPOSITIONS, METHODS AND SYSTEMS FOR AEROSOL DRUG DELIVERY | HAGHIGHATIAN, MINA | 17d overdue |
| 18256484 | METHODS OF PRODUCING ADENOVIRUS | GRIZER, CASSANDRA SENN | 9d |
| 18855182 | PREDICTING ALBUMINURIA USING MACHINE LEARNING | HEIN, DEVIN C | 12d |
| 18564778 | METHODS OF TREATING BREAST CANCER | FETTEROLF, BRANDON J | 16d |
| 18855064 | PREDICTING DISEASE PROGRESSION IN PORTAL HYPERTENSION USING MACHINE LEARNING | REICHERT, RACHELLE LEIGH | 70d |
| 19099577 | METHODS FOR DETECTING METABOLITES USING A MICROFLUIDIC-BASED CE-MS SYSTEM | GAMBLE JR, RANDALL LEE | — |
| 18870743 | COMBINATION THERAPY FOR TREATING CANCER | KOSAR, ANDREW D | — |
| Art Unit | Apps |
|---|---|
| 1672 | 3 |
| 3686 | 2 |
| 1626 | 2 |
| 1636 | 2 |
| 1616 | 2 |
| 1795 | 1 |
| 1644 | 1 |
| 1628 | 1 |
| 1627 | 1 |
| 1662 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19099577 | METHODS FOR DETECTING METABOLITES USING A MICROFLUIDIC-BASED CE-MS SYSTEM | GAMBLE JR, RANDALL LEE | 1795 | §102§103§112 | Non-Final OA | — | Pending | Jan 29, 2025 |
| 18872994 | METHODS FOR UNIFIED CONCENTRATION AND BUFFER EXCHANGE | KRUSE, DAVID H | — | §103 | Non-Final OA | — | Pending | Dec 09, 2024 |
| 18870743 | COMBINATION THERAPY FOR TREATING CANCER | KOSAR, ANDREW D | — | §103 | Non-Final OA | — | Pending | Dec 02, 2024 |
| 18870598 | SOLID FORMS OF HETEROCYCLYLAMIDES AS IRAK4 INHIBITORS | CHICKS, ASHLI ARIANA | — | §103§112DP | Non-Final OA | — | Pending | Nov 29, 2024 |
| 18855064 | PREDICTING DISEASE PROGRESSION IN PORTAL HYPERTENSION USING MACHINE LEARNING | REICHERT, RACHELLE LEIGH | 3686 | §101§112 | Non-Final OA | 70d | Pending | Oct 08, 2024 |
| 18855182 | PREDICTING ALBUMINURIA USING MACHINE LEARNING | HEIN, DEVIN C | 3686 | §101§103 | Final Rejection | 12d | Pending | Oct 08, 2024 |
| 18853504 | COMBINATION THERAPY FOR TREATING CANCER | FETTEROLF, BRANDON J | — | §103DP | Non-Final OA | — | Pending | Oct 02, 2024 |
| 18837956 | METHODS OF TREATING PROSTATE CANCER | ROZOF, TIMOTHY R | — | §103 | Non-Final OA | — | Pending | Aug 13, 2024 |
| 18753316 | ANTIBODY MOLECULES AND CONJUGATES | PETRASH, HILARY ANN | 1644 | §112Other | Non-Final OA | 54d | Pending | Jun 25, 2024 |
| 18718844 | CERTAIN 3-AZABICYCLO[3.1.0]HEXANES AS GLP-1 RECEPTOR MODULATORS | CLARK, AMY LYNN | 1628 | §112 | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18666615 | SPIN CHAMBER FOR AN INHALER | RUSSELL, SYDNEY REYES | — | §103DP | Non-Final OA | — | Pending | May 16, 2024 |
| 18704133 | Novel Lipids For Delivery Of Nucleic Acid Segments | HASTINGS, ALISON AZAR | 1627 | §112 | Non-Final OA | — | Pending | Apr 24, 2024 |
| 18698343 | TREATMENT OF LUPUS | HAM, JIEUN | — | §102§103DP | Non-Final OA | — | Pending | Apr 03, 2024 |
| 18621483 | METHODS OF TREATING HOMOLOGOUS RECOMBINATION DEFICIENT CANCER | LI, RUIXIANG | — | §102Other | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18696034 | Use of Inhibitors to Increase Efficiency of Crispr/CAS Insertions | GOMEZ RODRIGUEZ, JULIO WASHINGTON | — | §102§103§112DP | Non-Final OA | — | Pending | Mar 27, 2024 |
| 18589200 | DOSE | WEN, SHARON X | — | §103DP | Non-Final OA | — | Pending | Feb 27, 2024 |
| 18439897 | COMPOSITIONS AND METHODS FOR IMPROVING THE EFFICACY OF CAS9-BASED KNOCK-IN STRATEGIES | COLLINS, CYNTHIA E | 1662 | §102§103 | Non-Final OA | — | Pending | Feb 13, 2024 |
| 18291671 | TREATMENT OF LUPUS | NATARAJAN, MEERA | — | §102 | Non-Final OA | — | Pending | Jan 24, 2024 |
| 18417379 | VACCINE | GRIZER, CASSANDRA SENN | 1672 | §103§112 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18413349 | OSIMERTINIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER | WEBB, WALTER E | 1612 | §103 | Final Rejection | — | Pending | Jan 16, 2024 |
| 18410094 | METHODS OF TREATING HEART FAILURE WITH REDUCED EJECTION FRACTION | OLSON, ANDREA STEFFEL | 1693 | §103 | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18542918 | TREATMENT OF AUTOIMMUNE DISEASE | DAHLE, CHUN WU | — | §102§103§112 | Non-Final OA | — | Pending | Dec 18, 2023 |
| 18539471 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | HEASLEY, MEGHAN CHRISTINE | 1626 | §112 | Non-Final OA | — | Pending | Dec 14, 2023 |
| 18564778 | METHODS OF TREATING BREAST CANCER | FETTEROLF, BRANDON J | 1626 | §102§103§112 | Non-Final OA | 16d | Pending | Nov 28, 2023 |
| 18554014 | COMPOSITIONS AND METHODS FOR SITE-SPECIFIC MODIFICATION | YU, DAVID TUYANG | 1635 | §102 | Non-Final OA | — | Pending | Oct 05, 2023 |
| 18549852 | METHODS FOR TREATING SMALL CELL LUNG CANCER AND OTHER NEUROENDOCRINE CANCERS | CHANDRAKUMAR, NIZAL S | 1625 | §103DPOther | Non-Final OA | 62d | Pending | Sep 08, 2023 |
| 18262934 | CLINICAL ENDPOINT ADJUDICATION SYSTEM AND METHOD | PATEL, SHERYL GOPAL | 3685 | §101 | Non-Final OA | 17d overdue | Pending | Jul 26, 2023 |
| 18248280 | TREATMENT OF FLARES IN LUPUS | XIE, XIAOZHEN | 1674 | DP | Final Rejection | — | Pending | Apr 07, 2023 |
| 18247014 | COMPOUNDS AND THEIR USE IN TREATING CANCER | TOWNSLEY, SARA ELIZABETH | 1629 | §112 | Final Rejection | 87d overdue | Pending | Mar 28, 2023 |
| 18171735 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | AULAKH, CHARANJIT | 1621 | DP | Non-Final OA | — | Pending | Feb 21, 2023 |
| 18001643 | METHODS OF IMPROVING PROTEIN EXPRESSION | ZAHORIK, AMANDA MARY | 1636 | §112 | Non-Final OA | — | Pending | Dec 13, 2022 |
| 17917333 | COMPOSITIONS AND METHODS FOR IMPROVED SITE-SPECIFIC MODIFICATION | ALLEN, SARAH ELIZABETH | 1637 | §101§102§103§112DP | Non-Final OA | 22d overdue | Pending | Oct 06, 2022 |
| 17772187 | DRY POWDER FORMULATIONS CONTAINING LEUCINE AND TRILEUCINE | HAGHIGHATIAN, MINA | 1616 | §103 | Non-Final OA | 19d overdue | Pending | Apr 27, 2022 |
| 17754844 | MODULATORS OF PNPLA3 EXPRESSION | CHONG, KIMBERLY | 1636 | §102§103§112 | Non-Final OA | 69d | Pending | Apr 13, 2022 |
| 18590826 | COMPOSITIONS, METHODS AND SYSTEMS FOR AEROSOL DRUG DELIVERY | HAGHIGHATIAN, MINA | 1616 | §103§112 | Non-Final OA | 17d overdue | Pending | Feb 28, 2024 |
| 18577168 | COMPOSITIONS, METHODS AND SYSTEMS FOR AEROSOL DRUG DELIVERY | BECKHARDT, LYNDSEY MARIE | 1613 | §103§112DP | Non-Final OA | — | Pending | Jan 05, 2024 |
| 18256484 | METHODS OF PRODUCING ADENOVIRUS | GRIZER, CASSANDRA SENN | 1672 | §103§112 | Final Rejection | 9d | Pending | Jun 08, 2023 |
| 18256481 | METHODS OF PURIFYING ADENOVIRUS | CORNELIUS, CLAIRE ADRIENNE | 1672 | §103§112 | Non-Final OA | — | Pending | Jun 08, 2023 |
| 18252818 | PHARMACEUTICAL FORMULATION | PUTTLITZ, KARL J | 1646 | §102§103 | Final Rejection | 8d overdue | Pending | May 12, 2023 |
| 18012705 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATR INHIBITOR | KIM, SEONG JONG | 1623 | §103 | Non-Final OA | — | Pending | Dec 23, 2022 |
| 18052840 | COMPOSITION FOR TREATMENT AND PREVENTION OF COVID-19 | GODDARD, LAURA B | 1642 | §103 | Final Rejection | — | Pending | Nov 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial